

Glomerular Basement Membrane

[View the current Glomerular Basement Membrane InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Glomerular_Basement_Membrane.html) - Regularly Updated.

Recent Publications on Glomerular Basement Membrane:



- [Autoimmune kidney diseases.](#)
*The second most common cause of chronic renal failure is...*13th November, 2009
Section of Nephrology, Department of Clinical Sciences, Lund University,- *Autoimmun Rev.* 2009 Nov 10. ([DOI Direct Link](#))
- [\[A case of light chain deposition disease involving kidney and bone marrow with microangiopathic hemolytic anemia.\]](#)
*We report a case of light chain deposition disease in a 59-yr-old female...*7th November, 2009
Department of Laboratory Medicine, Eulji University School of Medicine,- *Korean J Lab Med.* 2009 Oct;29(5):384-9. ([DOI Direct Link](#))
- [The podocyte in diabetic kidney disease.](#)
*Approaching epidemic levels, diabetic kidney disease (DKD) is now the...*5th November, 2009
Kidney Research Centre, Chronic Disease Program, Ottawa Hospital Research-
ScientificWorldJournal. 2009 Oct 14;9:1127-39. ([DOI Direct Link](#))
- [\[Calcyphylaxis in a patient with end-stage renal disease in the course of systemic lupus erythematosus, diagnostic problems--case report\]](#)
*Calcyphylaxis consists in vascular calcium deposition and skin necrosis,...*28th October, 2009
Silesian Medical University in Katowice, Department of Internal Medicine,- *Pol Merkur Lekarski.* 2009 Aug;27(158):123-8.
- [IgA nephropathy associated with thin basement membrane with or without inflammatory disease: getting a different prognosis?](#)
*BACKGROUND: Thin basement membrane nephropathy (TBMN) patients with...*21st October, 2009
Department of Nephrology, the Second Affiliated Hospital, Nanchang- *Ren Fail.* 2009;31(6):452-6.
- [Stem cell therapies benefit Alport syndrome.](#)
*Patients with Alport syndrome progressively lose renal function as a...*17th October, 2009
Division of Matrix Biology, Beth Israel Deaconess Medical Center and- *J Am Soc Nephrol.* 2009 Nov;20(11):2359-70. Epub 2009 Oct 15. ([DOI Direct Link](#))
- [Leptospirosis and Goodpasture's syndrome: testing the aetiological hypothesis.](#)
*Leptospiral pathogens have a world-wide distribution and cause a spectrum...*15th October, 2009
WHO/OIE/FAO Collaborating Centre for Reference and Research on- *Ann Trop Med Parasitol.* 2009 Oct;103(7):647-51. ([DOI Direct Link](#))
- [Th1 and Th17 Cells Induce Proliferative Glomerulonephritis.](#)
*Th1 effector CD4+ cells contribute to the pathogenesis of proliferative...*13th October, 2009
*Centre for Inflammatory Diseases, Monash University Department of- *J Am Soc Nephrol.* 2009 Oct 9. (

[DOI Direct Link](#))

- [Immunological and non-immunological mechanisms of proteinuria.](#)
*Proteinuria as a general symptom of a broad range of different diseases...*10th October, 2009
HELIOS Kliniken, Department of Nephrology and Dialysis Faculty of- Minerva Urol Nefrol. 2009
Dec;61(4):385-96.
- [Ultrastructural changes in the glomerular filtration barrier and occurrence of proteinuria in Chinese patients with type 2 diabetic nephropathy.](#)
*AIM: Diabetic nephropathy (DN) is one of the most important causes of end...*10th October, 2009
Research Institute of Nephrology, Jingling Hospital, Nanjing University- Diabetes Res Clin Pract. 2009
Dec;86(3):199-207. Epub 2009 Oct 7. ([DOI Direct Link](#))
- [Dystroglycan in the Diagnosis of FSGS.](#)
*BACKGROUND AND OBJECTIVES: alpha- and beta-dystroglycan (DG), which link...*8th October, 2009
Department of Pathology, Vanderbilt University Medical Center, Nashville,- Clin J Am Soc Nephrol.
2009 Sep 24. ([DOI Direct Link](#))
- [Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.](#)
*AIM: Statins are widely used for their cholesterol-lowering effects and...*3rd October, 2009
Centre for Inflammatory Diseases, Monash University, Department of- Nephrology (Carlton). 2009
Oct;14(7):650-7. ([DOI Direct Link](#))
- [An IgA1-lambda-type monoclonal immunoglobulin deposition disease associated with membranous features in a patient with chronic hepatitis C viral infection and rectal cancer.](#)
*A 61-year-old man infected with hepatitis C virus developed urinary...*2nd October, 2009
Division of Nephrology and Rheumatology, Department of Internal Medicine,- Clin Exp Nephrol. 2009
Oct 1. ([DOI Direct Link](#))
- [Regulation of type IV collagen alpha chains of glomerular epithelial cells in diabetic conditions.](#)
*An early feature of diabetic nephropathy is the alteration of the...*2nd October, 2009
Department of Pediatrics, Chungbuk National University, Cheongju, Korea.- J Korean Med Sci. 2009
Oct;24(5):837-43. Epub 2009 Sep 24. ([DOI Direct Link](#))
- [Modeling of Human Anti-GBM Antibody-alpha3\(IV\)NC1 Interactions Predicts Antigenic Cross-Linking through Contact of Both Heavy Chains with Repeating Epitopes on alpha3\(IV\)NC1.](#)
*Background/Aims: Patients with anti-glomerular basement membrane diseases...*30th September, 2009
University of Pennsylvania, Philadelphia, Pa., USA.- Am J Nephrol. 2009;30(5):474-480. Epub 2009
Sep 28. ([DOI Direct Link](#))

Glomerular Basement Membrane Patents:



- 7425543- [Microencapsulated materials and method of making same](#)
- 7459531- [50 Human secreted proteins](#)
- 7465445- [Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM](#)
- 7465766- [Hydroxyphenyl cross-linked macromolecular network and applications thereof](#)
- 7470428- [Compositions and methods related to TIM-3, a Th1-specific cell surface molecule](#)
- 7473421- [Humanized anti-CCR2 antibodies and methods of use therefor](#)
- 7482013- [Albumin fusion proteins](#)

- 7488719- [Wound and cutaneous injury healing with a nucleic acid encoding perlecan](#)
- 7488792- [Collagen-binding molecules that selectively home to tumor vasculature and methods of using same](#)
- 7498027- [Methods of treatment using human tumor necrosis factor receptor TR17 antibodies](#)
- 7498298- [Monomethylvaline compounds capable of conjugation to ligands](#)
- 7459446- [Treatment of diabetes with copper binding compounds](#)
- 7455835- [Methods for treating immune system diseases using a soluble CTLA4 molecule](#)
- 7449184- [Fixed dosing of HER antibodies](#)
- 7425616- [Use of C-reactive protein to treat immune complex-mediated renal disease](#)
- 7425619- [Fc.gamma.RIIB specific antibodies and methods of use thereof](#)
- 7425620- [Fc.gamma.RIIB-specific antibodies and methods of use thereof](#)
- 7425622- [Antibodies against C3a receptor](#)
- 7426441- [Methods for determining renal toxins](#)
- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7439230- [Methods of treatment using CTLA4 mutant molecules](#)
- 7441666- [Process for producing an asymmetric porous film](#)
- 7442775- [Humanized anti-CCR2 antibodies and methods of use therefor](#)
- 7446176- [12 human secreted proteins](#)
- 7501391- [Treatment of transplant survival](#)
- 7504105- [Treatment using antibodies to cytokine receptor common gamma chain like](#)
- 7569384- [Albumin fusion proteins](#)
- 7576053- [Methods and compositions for treating degenerative bone disorders](#)
- 7584059- [Inhibition of immune complex formation](#)
- 7585840- [Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease](#)
- 7592010- [Albumin fusion proteins](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7597889- [Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)
- 7608429- [Methods and compositions for increasing antibody production](#)
- 7566539- [Anti-CCR2 antibodies and methods of use therefor](#)
- 7566450- [Humanized anti-CCR2 antibodies and methods of use therefor](#)
- 7560112- [Anti-il-6 antibodies, compositions, methods and uses](#)
- 7504388- [Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7511019- [Method of treating coronary artery disease by administering FGF-4](#)
- 7514081- [Methods of inhibiting an immune response with anti-human endokine alpha antibodies](#)
- 7514458- [Anti-cytokine heterocyclic compounds](#)
- 7521424- [Albumin fusion proteins](#)
- 7521542- [Humanized Fc.gamma.RIIB-specific antibodies and methods of use thereof](#)
- 7528236- [Humanized anti-beta7 antagonists and uses therefor](#)
- 7531511- [Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administering FGF-2](#)
- 7611893- [Metal-binding therapeutic peptides](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

